OpenAI acquires Orchestra Bio
OpenAI acquires Orchestra Bio to expand AI into biopharma drug development
OpenAI is acquiring Orchestra Bio to embed AI-powered operations into life sciences R&D workflows, targeting biopharma teams seeking to accelerate drug development. The move signals OpenAI's expansion beyond general-purpose AI into high-value vertical markets where compute and model capabilities can compress research timelines. For the AI industry, this represents a pattern of frontier labs making strategic acquisitions to own applied AI pipelines in regulated, capital-intensive sectors.